Vivos Therapeutics launches restructuring plan targeting $3.6 million annual savings from Q4 2026

The company targets USD 3.6 million in annual cost savings starting Q4 2026, with additional reductions effective Oct. 1, 2026, and expects full run-rate impact in Q4. Vivos targets cash-flow positive results by late 2026 or early 2027 and keeps its profitability target for 2027.